Teva Pharmaceuticals Presents Forward-Looking Financial Guidance at J.P. Morgan Conference

Summary

On January 11, 2026, Teva Pharmaceutical Industries Ltd. issued a press release providing financial guidance for 2025 and a forward-looking outlook for 2026 and beyond. The company expects 2025 revenues between $16.8 and $17.0 billion, operating margin between 26.2% and 27.1%, and adjusted EBITDA between $4.8 and $5.0 billion. For 2026, Teva anticipates flat to slightly down revenues compared to 2025, with operating profit growing and adjusted EBITDA increasing. The company also provided a path to achieving 2027 targets and additional 2030 targets, emphasizing disciplined capital allocation and securing an investment-grade credit rating.